meningococcal group B vaccine

(redirected from Bexsero)

meningococcal group B vaccine

(me-nin-go-kok-al groop B vax-seen),

Bexsero

(trade name),

Trumenba

(trade name)

Classification

Therapeutic: vaccines immunizing agents
Pharmacologic: antigens
Pregnancy Category: B

Indications

Bexsero—Provides active immunization against invasive meningococcal disease caused by 3 strains of Neisseria meningitidis serogroup B (strains prevalent in the US). Tremenba—Provides active immunization against invasive meningococcal disease caused by 4 strains of Neisseria meningitidis serogroup B (strains prevalent in the US).

Action

Induces production of antibodies to several strains of serogroup B Neisseria meningitidis.

Therapeutic effects

Prevention of invasive meningococcal disease.

Pharmacokinetics

Absorption: Well absorbed following IM administration.
Distribution: Unknown.
Metabolism and Excretion: Unknown.
Half-life: Unknown.

Time/action profile (antibody response)

ROUTEONSETPEAKDURATION
IMwithin 2 mounknownunknown

Contraindications/Precautions

Contraindicated in: Severe allergic reaction to a previous dose; Latex allergy (Bexsero tip caps contain latex).
Use Cautiously in: Geriatric: Safe and effective use in patients >65 yr has not been established; Lactation: Use cautiously if breastfeeding; Obstetric: Use during pregnancy only if clearly needed; Pediatric: Safe and effective use in children <10 yr not established (>90% risk of fever in infants <12 mo).

Adverse Reactions/Side Effects

Central nervous system

  • fatigue (most frequent)
  • headache (most frequent)

Gastrointestinal

  • nausea (most frequent)
  • diarrhea
  • vomiting

Local

  • injection site reactions (most frequent)

Musculoskeletal

  • arthralgia (most frequent)
  • mylagia (most frequent)

Miscellaneous

  • allergic reactions including anaphylaxis
  • chills (most frequent)
  • fever
  • syncope

Interactions

Drug-Drug interaction

Concurrent use of immunosuppressives may ↓ the desired immune response.

Route/Dosage

Bexsero

Intramuscular (Adults and Children 10–25 yr) Two 0.5 ml doses one mo apart.

Trumenba

Intramuscular (Adults and Children 10–25 yr) 0.5 ml followed by a second dose 2 mo later and a third dose 4 mo after the second dose.

Availability

Suspension for IM injection (Bexsero tip caps contain latex): 0.5 ml in pre-filled syringes

Nursing implications

Nursing assessment

  • Monitor for signs and symptoms of allergic reaction (dyspnea, rash, hives, swelling of face, lips, or throat). Keep epinephrine, an antihistamine, and resuscitation equipment close by in the event of an anaphylactic reaction.
  • Assess for latex allergy. Bexsero tip cap contains latex.
  • Assess for syncope. Make patient is sitting or lying down during and immediately following injections.

Potential Nursing Diagnoses

Risk for infection (Indications)

Implementation

  • Intramuscular: Shake syringe vigorously for a homogenous white suspension; do not use if solution has separated, discolored, or contains particulate matter. Administer 0.5 mL IM into deltoid muscle of upper arm. Do not mix with other vaccines in same syringe.

Patient/Family Teaching

  • Explain purpose of vaccine to patient/parent. Emphasize need for 2 doses of immunization series for Bexseroor 3 doses for Tremenba.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

  • Prevention of invasive meningococcal disease including meningitis.
Drug Guide, © 2015 Farlex and Partners
References in periodicals archive ?
These vaccines include Prevnar/ Prevnar 13, Gardasil/ Gardasil 9, Vaxigrip, Fluzone, Flublok, Varivax, Proquad, Menactra, Fluarix/ FluLaval, Pneumovax 23, Havrix/ Twinrix/ Engerix-B, Priorix, Priorix Tetra, Varilrix, M-M-R II, Adacel, Boostrix, Menveo, Bexsero, Cervarix, Shingrix, Trumenba, Rotateq, Pentacel, Pentaxim, Imovax, Hexaxim, Zostavax, Rotarix, Sunflorix, Pediarix, Infanrix, Ticovac, Biken Ha, Tetrabik, Mearubik, Varicella (MTP), Jebik V, Flumist/ Fluenz, Bio Thrax, Dukoral, In Live, Ixiaro, HeaLive, In Live, BiLive, EasySix, Imvamune, and Anflu.
Europe sales decreased 1% AER, 1% CER as growth from Tivicay and Triumeq was more than offset by continued generic competition to Epzicom and Avodart as well as a decrease in Bexsero sales largely due to the completion of the vaccination of catch-up cohorts in certain markets which benefited Q2 2017.
In 2013, a serogroup B meningococcal (MenB) vaccine, MenB-4C (Bexsero; GlaxoSmithKline, https://www.gsk.com) (6), became available for outbreak response via a Centers for Disease Control and Prevention (CDC)-sponsored expanded access investigational new drug protocol.
During his time at Novartis, he contributed to the successful development and approval of the breakthrough Bexsero Meningitis B vaccine.
* Designates the use of serogroup B meningococcal vaccine (MenB) (Bexsero, GlaxoSmithKline; Trumenba, Pfizer) in pregnant women as "Precaution" (orange).
It means an estimated 11 MILLION youngsters are currently unvaccinated as only babies born after the introduction of the anti-MenB Bexsero vaccine in May 2015 have been given inoculation on the NHS.
The Bexsero Pregnancy Registry (877-413-4759) is open to patients who have received the meningococcal group B vaccine (Bexsero).
It is not clear that Bexsero, a group B meningococcal outer-membrane-vesicle (OMV) vaccine currently licensed in the United States, will offer similar protection against gonorrhea as that provided by the vaccine studied in New Zealand, but there are important similarities.
The typical net profit ranges from $21.50 for high-dose influenza vaccine to, at the top end, $47.41 for meningococcal group B vaccine (Bexsero) and $49.58 for recombinant human papillomavirus 9-valent vaccine (Gardasil-9).
Vaccines sales were up 7% AER, 13% CER, primarily driven by sales of Shingrix in the US as well as increased demand for Bexsero and Hepatitis vaccines, partly offset by declines in Established Vaccines and Menveo.
M2 EQUITYBITES-February 9, 2018-US Food and Drug Administration grants breakthrough therapy designation for GlaxoSmithKline's Bexsero